Bezinga: Canadian insurance provider to cover off-label use of ketamine for treating depression

I had the chance to answer some questions for this Bezinga article explaining the recent news from Canada. I explain how Cedar has been able to use Spravato as a treatment with insurance coverage. Unfortunately, given the current off-label use of ketamine for depression and other treatment-resistant conditions, FDA approval has yet to be granted, which means almost always insurance companies won’t cover this kind of treatment. As more and more research supporting ketamine for mental illness emerges, I’m hopeful these kinds of structural changes will continue.